The Largest Neurotech Seed Round Ever
Merge Labs has closed a $252 million seed round — making it one of the largest seed-stage investments in the history of neurotechnology. The round was led by Bain Capital with participation from OpenAI, Khosla Ventures, and Lightspeed Venture Partners.
What They're Building
Merge Labs is developing a high-bandwidth brain-computer interface (BCI) designed to bridge the gap between human cognition and AI systems. Unlike earlier-generation BCIs focused purely on medical rehabilitation, Merge is positioning its technology at the intersection of neuroscience and artificial intelligence.
The company's approach combines:
- Advanced neural recording arrays with thousands of electrode channels
- AI-powered signal processing for real-time neural decoding
- A platform architecture that could scale from clinical applications to consumer use
Why This Matters for the Nervous System Space
Brain-computer interfaces represent the frontier of nervous system technology. While most current applications focus on restoring motor function in paralyzed patients, the long-term vision includes treating neurological conditions like epilepsy, depression, and chronic pain through direct neural modulation.
The Investor Signal
When OpenAI invests in a neurotechnology company, it signals a convergence between AI and neuroscience that the market has been anticipating. The investment thesis: understanding and interfacing with the brain is the next great computational challenge, and solving it requires the same scale of capital that went into large language models.
What to Watch
- FDA pathway decisions for non-medical BCI applications
- Competition with Neuralink, Synchron, and Paradromics
- Whether the company pursues clinical trials or consumer applications first
